Tubeless Insulin Pump Market - By Technology, By Distribution Channel, By End Use - Global Forecast, 2025 - 2034

Tubeless Insulin Pump Market Size

The global tubeless insulin pump market was valued at USD 1.9 billion in 2024. The market is expected to grow from USD 2.3 billion in 2025 to USD 12.2 billion in 2034, at a CAGR of 20.6% from 2025 to 2034, according to the latest report published by Global Market Insights Inc. This high growth is attributed to the increasing diabetes care expenditure, rising prevalence of diabetes, and injuries caused by conventional & invasive insulin pumps.

A tubeless insulin pump is a compact, wearable device used for insulin delivery in people with diabetes. The key players in the market are Insulet, Roche, Terumo, and MannKind Corporation. These players dominated the market by adopting various strategies such as product expansion and establishing global distribution networks.
 

The market has increased from USD 1 billion in 2021 and reached USD 1.4 billion in 2023, with a historic growth rate of 18.8%. This growth was primarily driven by the rising global prevalence of diabetes, along with increasing demand for user-friendly and discreet insulin delivery systems. Technological advancements such as integration with continuous glucose monitoring (CGM), Bluetooth-enabled remote control, and improved wearable designs have further fueled adoption. Additionally, the shift toward home care solutions, regulatory approvals, and strategic partnerships among key players has contributed to the market's expansion and accessibility.
 

The increasing prevalence of diabetes is emerging as a major driver for the tubeless insulin pump market. According to the International Diabetes Federation (IDF), in 2021, the global population having diabetes mellitus (DM) was estimated to be 463 million in 2019 and is going to increase to 700 million by 2045. This surge in diabetes cases is attributed to factors such as genetics, aging populations, and lifestyle changes. Additionally, obesity and excess body weight particularly abdominal obesity are major risk factors for Type 2 diabetes, contributing to insulin resistance and elevated blood sugar levels.
 

Additionally, rising awareness of diabetes and the need for effective insulin delivery therapies have driven demand for advanced diabetes care devices. Furthermore, continuous technological advancements, coupled with increasing healthcare expenditure on diabetes management, are further contributing to the growth of the tubeless insulin pump market.
 

A tubeless insulin pump is a medical device designed to manage diabetes by delivering a continuous supply of insulin without the need for traditional injections. These pumps are worn directly on the body and operate without external tubing, offering patients greater convenience and flexibility in managing their condition.
 

Tubeless Insulin Pump Market Trends

As diabetes prevalence rises globally, the tubeless insulin pump market is experiencing rapid growth, driven by innovations that increase comfort, precision, and patient safety in insulin delivery. These advancements are transforming diabetes management by reducing external tubing and enabling discreet, wearable solutions that integrate effortlessly into day-to-day life.
 

• Tubeless insulin pumps leverage advanced algorithms to dynamically manage insulin delivery and reduce the risks of hypoglycemia and hyperglycemia. When integrated with continuous glucose monitoring (CGM), these devices enable automated dosing without the need for frequent manual adjustments.
   
• Connectivity features further enhance usability. Modern tubeless insulin pump systems incorporate Bluetooth technology, enabling dashboard control and monitoring through smartphones or handheld controllers. This wireless integration also supports remote monitoring by caregivers and clinicians.
   
• For example, in 2024, the FDA approved the Omnipod 5 Automated Insulin Delivery System by Insulet Corporation the first and only tubeless automated insulin delivery system in the U.S. for both type 1 and type 2 diabetes. It offers customizable insulin profiles and real-time data sharing to support informed decision-making for patients and providers.
   
• Advancements in miniaturization and battery efficiency have led to smaller devices capable of delivering insulin for several days without recharging or frequent replacements. These improvements enhance user mobility while reducing the burden of device maintenance.
   
• Growing investment in closed-loop systems (artificial pancreas technology) is further transforming the market. By combining CGM, insulin pumps, and control algorithms, these systems autonomously deliver insulin with minimal user input. This nearly fully automated solution significantly improves glycemic control and enhances patient quality of life, thereby fueling market adoption.
   

Tubeless Insulin Pump Market Analysis

Based on technology, the tubeless insulin pump market is segmented into continuous glucose monitoring (CGM) integrated pumps and standard tubeless pumps. The continuous glucose monitoring (CGM) integrated pumps segment accounted for 62.5% of the market in 2024 due to its clinical reliability, continuous insulin delivery, and seamless integration with advanced CGM systems. The segment is expected to exceed USD 7.7 billion by 2034, growing at a CAGR of 20.8% during the forecast period.
 

On the other hand, the standard tubeless pumps segment held a market share of 37.5% in 2024. The growth of this segment can be attributed to its user-friendly design, improved comfort, and ability to be worn discreetly under clothing, making it a preferred choice for patients seeking convenience and lifestyle flexibility.
 

• CGM-integrated insulin pumps are gaining prominence since these systems can automatically manage a patient's insulin delivery without the patient's intervention, utilizing real-time glucose data. These devices allow for closed-loop configurations, sometimes referred to as artificial pancreas technology, improving glycemic control and reducing the risk of hypoglycemia significantly.
   
• Additionally, the CGM sensor-pump integrations provide the patient with the ability to make safer adjustments to their insulin doses as needed to maintain safety while providing improved quality of life during day-to-day activities.
   
• The standard tubeless pumps segment held a revenue of USD 713.8 million in 2024, with projections indicating a steady expansion at 20.3% CAGR from 2025 to 2034. The standard tubeless pumps, also known as patch pumps, are designed for discreet and flexible insulin delivery without external tubing. These devices are increasingly preferred due to their cost-effectiveness, offering a practical and affordable solution for long-term diabetes management.
   

Based on the distribution channel, the tubeless insulin pump market is segmented into brick and mortar and e-commerce. The brick and mortar segment accounted for 66.2% of the market in 2024.
 

• This segment includes hospital pharmacies, retail medical device outlets, and other physical outlets. The preference for brick and mortar channels is largely driven by the need for in-person consultation, device training, and insurance coordination, which are critical for first-time users of advanced insulin delivery systems.
   
• Moreover, healthcare providers often recommend or directly supply these devices through affiliated hospital pharmacies, ensuring that patients receive proper onboarding, including pump setup, CGM integration, and troubleshooting support.
   
• Additionally, the presence of certified diabetes educators and endocrinologists in these settings enhances patient confidence and adherence, further reinforcing the dominance of this segment.
   
• The e-commerce segment held a market share of 33.8% in 2024, driven by the increasing adoption of online platforms for medical device purchases, rising internet penetration, and the convenience of home delivery. Patients and caregivers are increasingly turning to e-commerce for tubeless insulin pumps due to the ease of comparing products, accessing user reviews, and leveraging subscription-based refill services.
   

Based on end use, the tubeless insulin pump market is segmented into homecare, hospitals & clinics, and other end users. The homecare segment accounted for USD 1.5 billion in 2024 and is set to witness notable growth in the coming years. This significant share is mainly attributed to the increasing preference for home-based diabetes management, especially among elderly and chronically ill patients.
 

• The rise in infectious diseases has accelerated the shift toward remote care, and patients now seek solutions that offer autonomy, comfort, and convenience. Tubeless insulin pumps, being compact, wearable, and discreet, align well with these expectations. Their integration with smartphone apps and continuous glucose monitoring (CGM) systems allows for real-time tracking and automated insulin delivery, making them ideal for home use.
   
• Additionally, favorable reimbursement policies and growing awareness about advanced diabetes technologies have further supported the adoption of insulin delivery devices in homecare settings.
   
• The hospitals and clinics segment continues to play a pivotal role in the insulin pump market, accounting for a significant share due to its central position in diabetes care delivery. The segment’s growth is driven by the increasing prevalence of diabetes, particularly among aging populations and individuals with obesity-related complications. Hospitals and clinics are often the first to adopt advanced insulin pump technologies, including tubeless and CGM-integrated systems, due to their access to specialized endocrinologists, diabetes educators, and certified pump trainers.
   
• Other end users segments, including long-term care facilities and rehabilitation centers, collectively contributed 6.9% of the market in 2024. These institutions cater to patients with chronic conditions, mobility limitations, or post-acute recovery needs, many of whom require consistent and simplified diabetes management.
   

North America dominated the global tubeless insulin pump market with the highest market share of 61.1% in 2024.
 

• The U.S. market was valued at USD 677 million and USD 799.2 million in 2021 and 2022, respectively. In 2024, the market size grew to USD 1.1 billion from USD 947 million in 2023.
   

• The U.S. tubeless insulin pump market benefits from widespread adoption of sophisticated diabetes technologies, including automated insulin delivery systems. Products such as Omnipod by Insulet have rapidly gained popularity as the ease of use gains acceptance, responsiveness to real-time glucose, and potential to prevent both hypoglycemia and hyperglycemia.
   
• Additionally, the country has relatively high purchasing power among the insured population, a strong awareness of emerging devices and technology, rising health care expenditure, and a health care system that is supportive of advanced treatments. These factors continue to drive sustained market growth.
   

Europe tubeless insulin pump market accounted for USD 692.4 million in 2024.
 

• The market in Europe is well-positioned for growth due to confidence in the use of automated insulin delivery systems in the diabetic population.
   
• High awareness levels among physicians, healthcare professionals, patients, and the public, along with strong advocacy from voluntary organizations, non-profits, and professional societies, have significantly improved access to tubeless insulin pump technologies.
   
• These initiatives promote integrated diabetes care that emphasizes early diagnosis, continuous glucose monitoring, and automated insulin delivery, further accelerating the adoption of tubeless insulin systems.
   
• Moreover, supportive reimbursement frameworks in countries such as Germany and France are reducing financial barriers, enabling broader adoption of advanced devices across diverse patient groups.
   

The Asia Pacific tubeless insulin pump market is anticipated to grow at the highest CAGR of 28.6% during the analysis timeframe.
 

• The rising prevalence of diabetes in the Asia-Pacific region is a significant public health concern, driven by rapid urbanization, lifestyle changes, and genetic predisposition. This growing burden is expected to place increasing pressure on healthcare systems, highlighting the urgent need for advanced solutions for diabetes management.
   
• For instance, according to the Diabetes Atlas by the International Diabetes Federation, the estimated number of adults aged 20-79 with diabetes in the Asia Pacific region in 2024 was approximately 249 million. These cases are reported across several countries in Southeast Asia and Western Pacific countries, with the leading contributors of the regional burden coming from China and India.
   
• Increasing healthcare infrastructure investments across emerging economies allows for more access to modern insulin delivery technologies. Hospitals and outpatient centers are beginning to adopt tubeless insulin pumps into their regular practice and allowing their patients to use these devices instead of insulin injection therapy.
   
• Furthermore, international collaborations are also accelerating progress in the region. Partnerships between local diabetes associations and global organizations are helping to improve training programs, promote awareness, and the rapid adoption of innovative devices like tubeless automated insulin delivery systems.
   

RoW Tubeless Insulin Pump Market

The rest of the world (RoW) tubeless insulin pump market is anticipated to record robust growth throughout the forecast period.
 

• The increasing prevalence of diabetes, coupled with efforts by governments to improve healthcare infrastructure, has created a fertile ground for innovative solutions like tubeless insulin pumps. Local health organizations are actively promoting better diabetes management practices, which encourage patients to seek out more convenient and efficient insulin delivery options.
   
• Additionally, the region's healthcare systems are beginning to adopt more advanced technologies in diabetes care, and with increasing investments in healthcare infrastructure, the potential for tubeless insulin pumps to gain traction is significant.
   
• Furthermore, cultural shifts toward prioritizing health and wellness are encouraging both patients and healthcare professionals to explore innovative diabetes management solutions.
   

Tubeless Insulin Pump Market Share

The market is consolidated, with leading players like Insulet, Roche, Terumo, MannKind Corporation, and Medtrum together holding around 89% of the market share. These companies maintain their leadership through innovation in wearable technology, integration with digital health platforms, and patient-centric design.
 

Major companies in the tubeless insulin pump space are strengthening their positions by focusing on enhanced design, AI-powered connectivity, and expanding access to wearable technology. Insulet, for instance, continues to lead with its Omnipod platform, offering a fully tubeless, wearable insulin pump that integrates with CGMs and smartphone apps. Its focus on automation, user convenience, and global expansion reinforces its dominance in the market.
 

Similarly, Roche is enhancing its diabetes care ecosystem by integrating predictive AI with CGM and insulin delivery systems. Its Accu-Chek Insight and mySugr platforms support personalized therapy and remote monitoring, positioning Roche as a digital health pioneer.
 

Further, other companies in the market are focusing on simplifying therapy and improving adherence, especially for newly diagnosed patients.
 

Tubeless Insulin Pump Market Companies

A few of the prominent players operating in the tubeless insulin pump industry include:

• Insulet
• MannKind Corporation
• Medtrum
• MicroTech
• Pharmasens
• Roche
• TERUMO
   
• Roche

Roche leads the tubeless insulin pump market with approximately 38% share in 2024. The company leverages its deep expertise in diagnostics and digital health to deliver integrated diabetes care solutions. Through its Accu-Chek and mySugr platforms, Roche enhances tubeless insulin delivery with data-driven insights, remote monitoring, and user-friendly interfaces. Its commitment to personalized care and global accessibility positions Roche as a trusted partner in long-term diabetes management.
 

• Insulet

Insulet has a strong presence in the tubeless insulin delivery market with its Omnipod platform, offering a fully wearable, automated insulin delivery system that integrates seamlessly into users lives. Its focus on simplicity, discretion, and smartphone connectivity empowers users with greater freedom and control. By combining clinical efficacy with lifestyle-friendly design, Insulet redefines diabetes management for both children and adults.
 

• Terumo

Terumo distinguishes itself with its Medisafe WITH detachable patch pump, designed for maximum flexibility and patient comfort. Its compact, tube-free, and detachable design supports active lifestyles, while intuitive remote control and sustainable components enhance usability and longevity. Terumo’s patient-centric innovation ensures that insulin therapy fits seamlessly into daily life.
 

Tubeless Insulin Pump Industry News:

• In June 2024, Insulet announced the full commercial launch of its Omnipod 5 device in the UK and the Netherlands. Omnipod 5 is the first and only tubeless automated insulin delivery (AID) system integrated with both of the leading CGM sensor brands, Dexcom and Abbott FreeStyle Libre. This product launch enabled the company to generate enhanced revenue and expand its product portfolio.
   
• In March 2021, Roche and Diabeloop announced a partnership to launch an automated insulin delivery solution that will integrate the Accu-Check insulin pump and Diabeloop’s monitoring system. This partnership helped the company generate an enhanced customer base.
   

The tubeless insulin pump market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million and from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Technology

• Continuous glucose monitoring (CGM) integrated pumps
• Standard tubeless pumps

Market, By Distribution Channel

• Brick and mortar
• E-commerce

Market, By End Use

• Homecare
• Hospitals & clinics
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• RoW